This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: A discussion of acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy)

Ticker(s): BBIO, PFE, ALNY

Who's the expert?

Institution: Stanford 

  • Cardiologist and Instructor at Stanford University School of Medicine.
  • Manages patients at the amyloid center at Stanford and directs the amyloid clinic at the Palo Alto VA.
  • Research focuses on Investigating the molecular mechanisms behind genetic risk factors for human cardiovascular disease focusing on amyloidosis, cardio-oncology, and atherosclerotic diseases.

Interview Questions

why do you think Part A of ATTRibute failed?

Added By: wilson_admin

What do you think of the Part B probability of success?

Added By: wilson_admin

How do you view acoramidis compared to other options

Added By: wilson_admin

Thinking of the three entrants into the CM arena - vutrisiran, eplontersen, and acoramidis, characterize what you believe are the differentiating advantages/disadvantages of each?

Added By: wilson_admin

Describe how you see the marketing shaking out with the emergence of three different players with three different solutions (vutrisiran, eplontersen, and acoramidis) in the aTTR-CM market? Are there unique patient types for each?

Added By: wilson_admin

What do you think the win ratio will be for ATTRibute-CM?

Added By: user718eef9c

In ATTR-ACT, the greatest benefit seemed to be in NYHA 1-2 irrespective of wt or m — that suggests that earlier disease responds better. Since the hypothesis is that ATTRibute-CM has a left-shifted population, should we expect a higher win ratio with AG10? 

Added By: user718eef9c

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.